keyword
MENU ▼
Read by QxMD icon Read
search

TIMI

keyword
https://www.readbyqxmd.com/read/27903394/-correlation-between-epicardial-adipose-tissue-thickness-and-slow-flow-of-non-obstructive-coronary-artery
#1
Q Wu, B Yang
Objective: To investigate the correlation between epicardial adipose thickness and slow flow of non-obstructive coronary artery. Methods: Clinical data of patients with coronary angiography examination evidenced stenosis<50% in our department from May 2014 to May 2015 were retrospectively analyzed.According to the level of TIMI in angiography, patients were divided into slow blood flow group (TIMI Ⅰ-Ⅱ, n=16) and normal blood flow group (TIMI Ⅲ, n=127). All epicardial adipose thickness was determined by echocardiography and data of biochemical data (fibrinogen, whole blood viscosity at high shear rate, erythrocyte aggregation index, platelet count, and platelet aggregation rate) were also analyzed...
November 24, 2016: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/27902833/evaluation-of-ischemic-and-bleeding-risks-associated-with-2-parenteral-antiplatelet-strategies-comparing-cangrelor-with-glycoprotein-iib-iiia-inhibitors-an-exploratory-analysis-from-the-champion-trials
#2
Muthiah Vaduganathan, Robert A Harrington, Gregg W Stone, Efthymios N Deliargyris, Ph Gabriel Steg, C Michael Gibson, Christian W Hamm, Matthew J Price, Alberto Menozzi, Jayne Prats, Steven Elkin, Kenneth W Mahaffey, Harvey D White, Deepak L Bhatt
Importance: In the context of contemporary pharmacotherapy, optimal antiplatelet management with percutaneous coronary intervention (PCI) has not been well established. Objective: To compare the ischemic and bleeding risks associated with glycoprotein IIb/IIIa inhibitors (GPIs) and a potent P2Y12 antagonist, cangrelor, in patients undergoing PCI. Design, Setting, and Participants: An exploratory analysis of pooled patient-level data from the 3 phase 3 Cangrelor vs Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PCI, CHAMPION PLATFORM, and CHAMPION PHOENIX) trials of patients undergoing elective or nonelective PCI...
November 30, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27899851/cutoff-value-of-admission-n-terminal-pro-brain-natriuretic-peptide-which-predicts-poor-myocardial-perfusion-after-primary-percutaneous-coronary-intervention-for-st-segment-elevation-myocardial-infarction
#3
Khairy Abdel-Dayem, Inas I Eweda, Ashraf El-Sherbiny, Marc O Dimitry, Wail Nammas
BACKGROUND: We explored the value of admission levels of N-terminal pro-brain natriuretic peptide (NTProBNP) that best predicts poor myocardial tissue perfusion following primary percutaneous coronary intervention (PPCI) in patients admitted with acute ST-segment-elevation myocardial infarction (STEMI). METHODS: We enrolled 90 consecutive patients admitted with acute STEMI who underwent PPCI and achieved post-procedural TIMI flow grade 3 in the infarct-related artery...
November 2016: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27899850/evaluation-of-short-and-long-term-efficacy-of-combined-intracoronary-administration-of-high-dose-adenosine-and-tirofiban-during-primary-percutaneous-coronary-intervention
#4
Yanbing Li, Qiang Li, Feiou Li, Min Zong, Guobin Miao, Xinchun Yang, Zichuan Tong, Jianjun Zhang
BACKGROUND: To assess the influence of combined intracoronary application of high-dose adenosine and tirofiban in primary percutaneous coronary intervention (PCI) on clinical events and cardiac function. METHODS: Our study evaluated consecutive patients with acute ST-segment elevation myocardial infarction undergoing primary PCI, who were randomly divided into adenosine group (n = 130) and control group (n = 128). Combined with thrombus aspiration and then intracoronary tirofiban, the adenosine group received intracoronary adenosine (2 mg) through the aspiration catheter 2 times...
November 2016: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27891513/clinic-predictive-factors-for-insufficient-myocardial-reperfusion-in-st-segment-elevation-myocardial-infarction-patients-treated-with-selective-aspiration-thrombectomy-during-primary-percutaneous-coronary-intervention
#5
Jinfan Tian, Yue Liu, Xiantao Song, Min Zhang, Feng Xu, Fei Yuan, Shuzheng Lyu
Background. Insufficient data are available on the potential benefit of selective aspiration and clinical predictors for no-reflow in STEMI patients undergoing primary percutaneous coronary intervention (PPCI) adjunct with aspiration thrombectomy. Objective. The aim of our study was to investigate clinical predictors for insufficient reperfusion in patients with high thrombus burden treated with PPCI and manual aspiration thrombectomy. Methods. From January 2011 till December 2015, 277 STEMI patients undergoing manual aspiration thrombectomy and PPCI were selected and 202 patients with a Thrombolysis in Myocardial Infarction (TIMI) thrombus grade 4~5 were eventually involved in our study...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27888764/clinical-characteristics-and-prognosis-of-acute-coronary-syndrome-in-young-women-and-men-a-systematic-review-and-meta-analysis-of-prospective-studies
#6
Qinghua Ma, Jinwen Wang, Jing Jin, Ming Gao, Fang Liu, Shanshan Zhou, Feng Tian, Jie Liu, Yuqi Liu, Yundai Chen
OBJECTIVES: The clinical characteristics and prognosis of young women (≤50years) with acute coronary syndrome (ACS) are still unclear. METHODS: A total of 5196 patients with ACS were enrolled from the cardiac center of Chinese PLA General Hospital and Anzhen Hospital. The clinical characteristics of these patients were analyzed. Then the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials electronic databases were searched from January 2001 to July 2016...
November 9, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27880927/very-low-risk-st-segment-elevation-myocardial-infarction-it-exists-and-may-be-easily-identified
#7
Felipe Díez-Delhoyo, María Jesús Valero-Masa, Jesús Velásquez-Rodríguez, Carolina Devesa-Cordero, Iago Sousa-Casasnovas, Miriam Juárez, Rocío Angulo-Llanos, Francisco Fernández-Avilés, Manuel Martínez-Sellés
BACKGROUND: Early discharge protocols have been proposed for ST-segment elevation myocardial infarction (STEMI) low risk patients despite the existence of few but significant cardiovascular events during mid-term follow-up. We aimed to identify a subgroup of patients among those considered low-risk in which prognosis would be particularly good. METHODS: We analyzed 30-day outcomes and long-term follow-up among 1.111 STEMI patients treated with reperfusion therapy...
November 17, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27870603/indirect-comparison-of-novel-oral-anticoagulants-in-women-with-nonvalvular-atrial-fibrillation
#8
Alex Moseley, Rami Doukky, Kim Allan Williams, Amir K Jaffer, Annabelle Santos Volgman
BACKGROUND: For nonvalvular atrial fibrillation (NVAF), novel oral anticoagulants (NOACs) have been found noninferior to warfarin for stroke/systemic embolization prevention, and major bleeding events. Recent meta-analysis of NOACs versus warfarin in atrial fibrillation (AF) showed that women on warfarin have greater risk of stroke/embolism than men, and when both are treated with NOACs, differences disappear. METHODS: NOACs differ in pharmacologic properties, thus they may differ from one another in their effects on women with AF...
November 21, 2016: Journal of Women's Health
https://www.readbyqxmd.com/read/27866133/bleeding-episodes-in-complete-staged-versus-culprit-only-revascularisation-in-patients-with-multivessel-disease-and-st-segment-elevation-myocardial-infarction-a-danami-3-primulti-substudy
#9
Golnaz Sadjadieh, Thomas Engstrøm, Steffen Helqvist, Dan Eik Høfsten, Lars Køber, Frants Pedersen, Peter Clemmensen, Erik Jørgensen, Kari Saunamäki, Hans-Henrik Tilsted, Henning Kelbæk, Lene Holmvang
AIMS: The aim of this study was to evaluate whether a staged in-hospital complete revascularisation strategy increases the risk of serious bleeding events in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. METHODS AND RESULTS: The DANAMI-3-PRIMULTI trial investigated whether a staged in-hospital complete revascularisation strategy improved outcome in patients with STEMI and multivessel disease. In this substudy, we investigated potential bleeding complications related to a second in-hospital procedure...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27859337/exposure-response-analyses-supporting-ticagrelor-dosing-recommendation-in-patients-with-prior-myocardial-infarction
#10
Daniel Röshammar, Joakim Nyberg, Tomas Andersson, Donald Stanski, Robert F Storey, Bengt Hamrén
The relationships between drug exposure and the composite risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke as well as the risk of TIMI major bleeding were estimated following long-term treatment with ticagrelor 60 or 90 mg twice daily in 20,942 patients with prior MI. These analyses support the primary reported efficacy and safety evaluations by showing that there were clear separations from placebo early in treatment with both doses, regardless of ticagrelor exposure, for both endpoints...
November 18, 2016: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27857514/the-use-of-bioceramics-in-endodontics-literature-review
#11
REVIEW
Stefan Jitaru, Ioana Hodisan, Lucia Timis, Anamaria Lucian, Marius Bud
BACKGROUND AND AIM: Bioceramics are ceramic compounds obtained both in situ and in vivo, by various chemical processes. Bioceramics exhibit excellent biocompatibility due to their similarity with biological materials, like hydroxyapatite. Bioceramics and multi-substituted hydroxyapatite or similar compounds have the ability to induce a regenerative response in the organism. The aim of this paper is to make a literature review on the main bioceramic materials currently used in endodontics and on their specific characteristics...
2016: Clujul Medical (1957)
https://www.readbyqxmd.com/read/27855726/helminth-parasites-of-south-american-fishes-current-status-and-characterization-as-a-model-for-studies-of-biodiversity
#12
J L Luque, F B Pereira, P V Alves, M E Oliva, J T Timi
The South American subcontinent supports one of the world's most diverse and commercially very important ichthyofauna. In this context, the study of South American fish parasites is of increased relevance in understanding their key roles in ecosystems, regulating the abundance or density of host populations, stabilizing food webs and structuring host communities. It is hard to estimate the number of fish parasites in South America. The number of fish species studied for parasites is still low (less than 10%), although the total number of host-parasite associations (HPAs) found in the present study was 3971...
November 18, 2016: Journal of Helminthology
https://www.readbyqxmd.com/read/27854064/the-rationale-for-and-clinical-pharmacology-of-prasugrel-5-mg
#13
REVIEW
Joseph A Jakubowski, David Erlinge, Dimitrios Alexopoulos, David S Small, Kenneth J Winters, Paul A Gurbel, Dominick J Angiolillo
Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients...
November 17, 2016: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/27846006/chest-pain-risk-scores-can-reduce-emergent-cardiac-imaging-test-needs-with-low-major-adverse-cardiac-events-occurrence-in-an-emergency-department-observation-unit
#14
Hao Wang, Katherine Watson, Richard D Robinson, Kristina H Domanski, Johnbosco Umejiego, Layton Hamblin, Sterling E Overstreet, Amanda M Akin, Steven Hoang, Meena Shrivastav, Michael Collyer, Ryan N Krech, Chet D Schrader, Nestor R Zenarosa
OBJECTIVE: To compare and evaluate the performance of the HEART, Global Registry of Acute Coronary Events (GRACE), and Thrombolysis in Myocardial Infarction (TIMI) scores to predict major adverse cardiac event (MACE) rates after index placement in an emergency department observation unit (EDOU) and to determine the need for observation unit initiation of emergent cardiac imaging tests, that is, noninvasive cardiac stress tests and invasive coronary angiography. METHODS: A prospective observational single center study was conducted from January 2014 through June 2015...
December 2016: Critical Pathways in Cardiology
https://www.readbyqxmd.com/read/27844422/intracoronary-eptifibatide-during-primary-percutaneous-coronary-intervention-in-early-versus-late-presenters-with-st-segment-elevation-myocardial-infarction-a-randomized-trial
#15
Ayman Elbadawi, Gerald Gasioch, Islam Y Elgendy, Ahmed N Mahmoud, Le Dung Ha, Haitham Al Ashry, Hend Shahin, Mohamed A Hamza, Ahmed S Abuzaid, Marwan Saad
INTRODUCTION: The role of intracoronary (IC) eptifibatide in primary percutaneous coronary intervention (PPCI) for ST segment elevation myocardial infarction (STEMI) and whether time of patient presentation affects this role are unclear. We sought to evaluate the benefit of IC eptifibatide use during primary PCI in early STEMI presenters compared to late STEMI presenters. METHODS: We included 70 patients who presented with STEMI and were eligible for PPCI. On the basis of symptom-to-door time, patients were classified into two arms: early (<3 h, n = 34) vs late (≥3 h, n = 36) presenters...
November 14, 2016: Cardiology and Therapy
https://www.readbyqxmd.com/read/27835698/a-simple-risk-stratification-model-for-st-elevation-myocardial-infarction-stemi-from-the-combination-of-blood-examination-variables-acute-myocardial-infarction-kyoto-multi-center-risk-study-group
#16
Kenji Yanishi, Takeshi Nakamura, Naohiko Nakanishi, Isao Yokota, Kan Zen, Tetsuhiro Yamano, Hirokazu Shiraishi, Takeshi Shirayama, Jun Shiraishi, Takahisa Sawada, Yoshio Kohno, Makoto Kitamura, Keizo Furukawa, Satoaki Matoba
BACKGROUND: Many mortality risk scoring tools exist among patients with ST-elevation Myocardial Infarction (STEMI). A risk stratification model that evaluates STEMI prognosis more simply and rapidly is preferred in clinical practice. METHODS AND FINDINGS: We developed a simple stratification model for blood examination by using the STEMI data of AMI-Kyoto registry in the derivation set (n = 1,060) and assessed its utility for mortality prediction in the validation set (n = 521)...
2016: PloS One
https://www.readbyqxmd.com/read/27819149/clinical-relevance-of-pharmacokinetic-and-pharmacodynamic-properties-of-edoxaban-when-treating-patients-with-atrial-fibrillation-and-heart-failure
#17
Nadia Aspromonte, Furio Colivicchi
Atrial fibrillation (AF) is an independent risk factor for stroke. It is most prevalent in the elderly and frequently coexists with heart failure (HF). The joint occurrence of AF and HF further worsens prognosis. The prevention of thromboembolism is crucial in the management of AF. In recent years, new oral anticoagulants (NOACs) have been licensed for the prevention of stroke and systemic embolism in patients with AF. Areas covered: This article reviews the key published studies on the pharmacology, clinical efficacy and safety of edoxaban, the latest NOAC to receive approval for the AF indication...
November 6, 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27818473/plasma-lipoprotein-associated-phospholipase-a2-level-is-an-independent-predictor-of-high-thrombus-burden-in-patients-with-acute-st-segment-elevation-myocardial-infarction
#18
Xiangqi Wu, Yingqiang Zhang, Zhiming Wu, Wei You, Fengshuo Liang, Fei Ye, Shaoliang Chen
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an independent risk factor for plaque rupture and atherothrombotic events. However, the associations between serum Lp-PLA2 level and thrombus burden in ST-segment elevation myocardial infarction (STEMI) patients remain unknown.We consecutively enrolled 351 STEMI patients who underwent primary percutaneous coronary intervention (pPCI). Patients were assigned to a high thrombus burden (HTB) group (n = 230) and a low thrombus burden (LTB) group (n = 121). Baseline data were recorded during hospital admission...
November 4, 2016: International Heart Journal
https://www.readbyqxmd.com/read/27817212/the-factor-xa-inhibitor-edoxaban-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation
#19
Joan Minguet, Helen M Sims, Katherine H Smith, Peter Bramlage
With the rising prevalence of nonvalvular atrial fibrillation (NVAF) in the general population, the development of new drugs for prevention of thromboembolic events is essential. Non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to present a number of advantages over conventionally used agents, such as predictable pharmacokinetics and no requirement for continuous anticoagulant monitoring. The most recently approved NOAC for the NVAF indication is edoxaban. Several subgroup analyses from the edoxaban phase III ENGAGE AF-TIMI 48 trial have now been published, alongside meta-analysis data comparing the four currently approved NOACs...
November 17, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27815268/relationship-of-platelet-reactivity-with-bleeding-outcomes-during-long-term-treatment-with-dual-antiplatelet-therapy-for-medically-managed-patients-with-non-st-segment-elevation-acute-coronary-syndromes
#20
Jan H Cornel, E Magnus Ohman, Benjamin Neely, Joseph A Jakubowski, Deepak L Bhatt, Harvey D White, Diego Ardissino, Keith A A Fox, Dorairaj Prabhakaran, Paul W Armstrong, David Erlinge, Udaya S Tantry, Paul A Gurbel, Matthew T Roe
BACKGROUND: The relationship between "on-treatment" low platelet reactivity and longitudinal risks of major bleeding dual antiplatelet therapy following acute coronary syndromes remains uncertain, especially for patients who do not undergo percutaneous coronary intervention. METHODS AND RESULTS: We analyzed 2428 medically managed acute coronary syndromes patients from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial who had serial platelet reactivity measurements (P2Y12 reaction units; PRUs) and were randomized to aspirin+prasugrel versus aspirin+clopidogrel for up to 30 months...
November 4, 2016: Journal of the American Heart Association
keyword
keyword
11432
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"